Corcept Therapeutics Incorporated
CORT
$57.08
$5.9211.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.20% | 12.79% | 17.92% | 25.71% | 30.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.20% | 12.79% | 17.92% | 25.71% | 30.93% |
| Cost of Revenue | 25.18% | 25.00% | 43.91% | 44.28% | 50.75% |
| Gross Profit | 12.00% | 12.60% | 17.53% | 25.45% | 30.65% |
| SG&A Expenses | 59.96% | 60.08% | 64.63% | 63.08% | 63.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.28% | 33.30% | 39.39% | 39.20% | 43.25% |
| Operating Income | -107.41% | -67.41% | -54.42% | -20.62% | -9.44% |
| Income Before Tax | -91.09% | -58.84% | -46.79% | -15.74% | -3.54% |
| Income Tax Expenses | -1,758.69% | -263.63% | -171.76% | -131.27% | -90.81% |
| Earnings from Continuing Operations | -64.67% | -29.43% | -25.18% | 6.09% | 13.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.67% | -29.43% | -25.18% | 6.09% | 13.53% |
| EBIT | -107.41% | -67.41% | -54.42% | -20.62% | -9.44% |
| EBITDA | -106.03% | -66.64% | -53.74% | -19.97% | -9.16% |
| EPS Basic | -64.77% | -30.18% | -26.14% | 4.46% | 11.77% |
| Normalized Basic EPS | -90.96% | -59.24% | -47.39% | -16.88% | -4.90% |
| EPS Diluted | -69.68% | -33.60% | -30.55% | -0.44% | 8.96% |
| Normalized Diluted EPS | -96.19% | -61.33% | -50.43% | -20.47% | -7.27% |
| Average Basic Shares Outstanding | 0.37% | 0.61% | 0.89% | 1.18% | 1.23% |
| Average Diluted Shares Outstanding | 0.21% | 5.79% | 7.28% | 6.62% | 4.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |